Portable MRI enhanced by AI cleared for prostate imaging

A manufacturer of compact MRI machines that leverage AI to upgrade image quality has received FDA’s blessing to market its technology in the U.S.

Oakland, California-based Promaxo announced the development March 8, saying the agency had granted 510(k) clearance for its product to be used in image-guided prostate procedures such as biopsies.

The company says the system is small enough for installation in urologists’ offices and outpatient surgery suites, no shielding or facility upgrades needed.

The product “incorporates patented technologies to capture, reconstruct and display magnetic resonance images of prostate and surrounding tissues,” Promaxo says. “The proprietary device leverages pre-programmed sequences and artificial intelligence to enhance image quality.”

Announcement here.

Dave Pearson

Dave P. has worked in journalism, marketing and public relations for more than 30 years, frequently concentrating on hospitals, healthcare technology and Catholic communications. He has also specialized in fundraising communications, ghostwriting for CEOs of local, national and global charities, nonprofits and foundations.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.